Givinostat for wheelchair-bound boys with Duchenne muscular dystrophy
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This Phase 3 trial tests givinostat to see if it can improve safety and functional outcomes in boys with Duchenne muscular dystrophy who cannot walk. You might be a candidate if you meet age, genetic diagnosis, wheelchair-level mobility, and specific arm-strength/respiratory/heart criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a male between 9 and 17 years old at screening (18 or older cannot join)
- Have a confirmed genetic diagnosis of Duchenne muscular dystrophy (DMD)
- Be wheelchair-bound and unable to complete the 10-meter walking test in the required way
- Score in the required range on the Upper Limb test (PUL version 2.0) at entry
- If using heart or steroid medicines for DMD-related heart problems, the doses must be stable for at least 1 month (for heart meds) and 6 months (for steroids)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
This trial tests a gene therapy called GNR-097 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help improve muscle function, and the study will check how safe and effective it is.
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
This trial tests a new daily pill called SAT-3247 for boys with Duchenne muscular dystrophy (DMD) who are still able to walk. The goal is to see if it can help slow muscle decline.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.